Treatment Of Blepharitis And Associated Dry Eye Disease By Plasma Emission

To evaluate the efficacy and safety of treatment of blepharitis and meibomian gland dysfunction by plasma emission (JETT PLASMA LIFT MEDICAL) by non-ablative treatment. The device based on the physical principle of direct current performs membrane depolarization, reversible electroporation, and generates heat. This process can change the polarity of the cell membrane, permeability for nutrients and associated anti-inflammatory effect, improve the liquefaction of the volume of the meibomian gland, dissolve the plug on its orificium and make tears more balance

Prospective, multicentred, randomized, and single-blind controlled study,Germany,Czeck republik

A total of 77 patients (age 34- 88 years) was treated with plasma emission by silver applicator by acceptable intensity (1-6). These patients were treated four times (spacing after one week), followed by follow-up after 1 week (1st check-up), 1 month (2nd check-up), and 3 months (3rd check-up). The placebo group, served as the control group, was treated with an intensity of 0.

The primary objective was to evaluate the changes in the OSDI index and tears break-up time test (TBUT) during the treatment. The other goals were to monitor the changes in meibography by Oculus Keratograph 5M together with the measurement of the height of the tear meniscus and NIKBUT. Other goals were to verify the treatment’s safety and monitor side effects.

There has been an improvement in OSDI in 97,4% at the final check-up. The average value in the group of patients with active treatment was 38,92 at the 1st treatment, then decreased to 24,44 (an improvement of 37 %) and during check-ups to further reduction of values around 19 (19,47; 18,39; 19,99 respectively). The controlled group has an improvement from an average of 28,9 to 23,53, respectively 19 % improvement. The average value of TBUT in the group of actively treated patients was 7,5 (3,5-14) at the beginning, followed by an increase in other treatments to 8,7; 9,3, and 10,3 in an average improvement of 21 %. Subsequent check-ups improved TBUT up to 10,4 (±2,461, improvement of 40 %). 

 

This study has  confirmed the efficacy and safety (the evaluation did not reveal any adverse events) of treatment with the medical device JETT PLASMA LIFT MEDICAL with silver applicators to alleviate the condition or completely cure blepharitis, Meibomian gland dysfunction indication, and associated dry eye disease. 

 

Financial Disclosure: NONE